statistically

[키워드] 1:1 95% CI accounted addition adverse event adverse events age All trial participants analyzed antiviral activity assigned blind by mouth calculated center Chain Reaction Characteristics clearance of SARS-CoV-2 clinical clinical trial confirmation contagious period cough COVID COVID-19 COVID-19 testing decrease determined by diagnose Duration duration of symptom Efficacy enrolled Enrollment exclusion criteria fecal Fecal sample finding group groups headache Headaches Hospitalization Importance in vitro individual Infection intention-to-treat investigators Laboratory Massachusett Massachusetts mean difference mean survival time measure men Mild mild to moderate Mild to moderate COVID-19 mild to moderate symptoms moderate Moderate COVID-19 MONITOR mouth network niclosamide no significant difference objective oral Oropharyngeal participant Participants Patient patients receiving placebo Phase 2 Placebo placebo group placebo-controlled clinical trial platform Point polymerase chain polymerase chain reaction positive primary end point proportion Randomized randomized clinical trial Randomly receive receiving Registration Relevance reported respiratory respiratory sample Respiratory samples Result Safe sample collection Sample size SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 clearance setting shedding significant effect significantly Standard of care statistically Symptom symptom duration symptom resolution Symptoms the placebo group therapy treat Treatment treatment for COVID-19 treatment groups Trial trial participants Tuft vaccination Viral viral clearance viral shedding was collected
[DOI] 10.1001/jamanetworkopen.2021.44942 PMC 바로가기 [Article Type] Randomized Controlled Trial